PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayIn critically ill intensive care unit patients presenting with concurrent orthopedic trauma and sepsis, elevated glycemic variability functions as a powerful, independent predictor of both short- and long-term all-cause mortality, according to a retrospective observational cohort investigation published in the Journal of Orthopaedics and Traumatology. The study established that blood glucose fluctuations do not follow a simple linear trajectory of risk but instead demonstrate a marked J-shaped nonlinear association with mortality across all observed time points. By examining clinical records spanning fourteen years, the research team identified a consistent inflection threshold at an average coefficient of variation of 21.3 percent, beyond which patient mortality risk escalates sharply. The investigation further revealed that incorporating glycemic variability into established clinical risk scoring systems, specifically the Oxford Acute Severity of Illness Score and the Charlson Comorbidity Index, yields statistically significant improvements in predictive discrimination, underscoring the prognostic utility of metabolic stability alongside traditional static physiological measurements.
Severe orthopedic trauma frequently stems from high-energy mechanical incidents, including road traffic collisions and serious occupational falls at industrial or construction sites, imposing a substantial clinical and operational burden on global healthcare infrastructures. International epidemiology indicates that vehicular collisions alone produce millions of skeletal fractures each year, with femoral shaft fractures accounting for between one million and nearly three million cases worldwide. Severe musculoskeletal trauma triggers an aggressive systemic inflammatory response and acute metabolic stress, both of which severely compromise immune homeostasis. When these vulnerable patients develop sepsis, defined as a dysregulated host response to infection, the combined traumatic and infectious insult creates a compounding cascade of multi-organ dysfunction, historically linked in the clinical literature to in-hospital mortality rates ranging from 9.5 percent to 19.7 percent.
While systemic stress in critical illness routinely manifests as absolute hyperglycemia, clinical focus has increasingly shifted toward glycemic variability, which captures the frequency and amplitude of blood glucose oscillations over time. Prior clinical studies have noted that fluctuating glucose levels provoke greater cellular oxidative stress, heightened endothelial injury, and accelerated proinflammatory cytokine release than sustained, stable high glucose concentrations alone. Although elevated glycemic variability has been independently correlated with adverse clinical outcomes across diverse populations, such as individuals with diabetes, severe burn injuries, and acute cardiovascular disorders, its distinct prognostic impact within septic orthopedic trauma cohorts remained previously undefined. Understanding whether glucose fluctuations independently modify survival in this specific group was therefore essential to determine whether glycemic stability constitutes a distinct, clinically actionable therapeutic target.
To investigate this relationship, the investigators conducted a comprehensive retrospective cohort analysis utilizing data extracted from the Medical Information Mart for Intensive Care IV database, designated as version 3.1. The study cohort comprised 1,946 adult patients aged eighteen years or older who satisfied two mandatory diagnostic criteria: an admission diagnosis of skeletal fracture trauma categorized under International Classification of Diseases codes, and a concurrent diagnosis of sepsis fulfilling standard Sepsis-3 definitions. Specific orthopedic trauma inclusion encompassed ICD-9 codes 800 through 829 alongside ICD-10 diagnostic blocks S12, S22, and S32. Sequential exclusion criteria removed patients without fracture trauma, individuals discharged from the intensive care unit or who died within twelve hours of admission to ensure adequate longitudinal data, patients lacking confirmed sepsis, and cases with fewer than two blood glucose measurements.
Within the analytical protocol, glycemic variability was quantified using the coefficient of variation, calculated by dividing the standard deviation of all intermittent blood glucose measurements recorded during an individual patient’s intensive care stay by their mean blood glucose value, multiplied by one hundred percent. The metric was selected because it naturally normalizes glucose fluctuations against each patient’s baseline mean concentration, permitting direct comparisons across diverse physiological baselines. Blood glucose sampling was conducted as part of routine, clinically directed intensive care management via point-of-care fingerstick testing or arterial and venous blood gas analyzers, with sampling intervals typically ranging between one and four hours based on clinical stability and insulin infusion protocols. Continuous glucose monitoring devices were not utilized. The primary study endpoint was all-cause mortality, systematically measured at four separate follow-up milestones: during the index hospital admission, at thirty days, at ninety days, and at three hundred and sixty-five days following intensive care admission.
The overall cohort of 1,946 patients presented with high illness severity and substantial physiological compromise, displaying an average age of 62.68 years, a male predominance of 64.1 percent, and rare self-reported histories of smoking or alcohol abuse. Chronic comorbidities were highly prevalent, evidenced by a mean Charlson Comorbidity Index of 3.97; notably, 35.0 percent had hypertension, 24.3 percent suffered from congestive heart failure, 22.3 percent had diabetes mellitus, and 22.0 percent presented with chronic pulmonary disease. Acute kidney injury affected 84.5 percent of the cohort, while 70.1 percent required mechanical invasive ventilation. Baseline severity scores were markedly elevated, with a mean Acute Physiology Score III of 48.71, Simplified Acute Physiology Score II of 38.22, Sequential Organ Failure Assessment score of 6.65, Oxford Acute Severity of Illness Score of 34.78, and Glasgow Coma Scale score of 10.81. The cohort experienced high overall mortality rates across all observation periods: 16.0 percent in-hospital, 19.8 percent at thirty days, 26.4 percent at ninety days, and 33.9 percent at one year.
When the study population was stratified across ascending quartiles of glycemic variability, marked clinical gradients emerged across nearly all baseline physiological parameters. Compared with patients in the lowest quartile, individuals categorized in the highest glycemic variability quartile were significantly older, averaging 65.78 years compared to 60.14 years, and exhibited progressively worse mean severity scores across the Acute Physiology Score III (rising from 41.94 to 57.51), Simplified Acute Physiology Score II, and Sequential Organ Failure Assessment score. The prevalence of preexisting diabetes increased from 11.9 percent in the lowest quartile to 41.5 percent in the highest, while congestive heart failure and acute kidney injury displayed parallel upward trends. Patients in higher variability quartiles also presented with significantly higher baseline red cell distribution width, blood urea nitrogen, serum creatinine, and admission glucose, coupled with lower hemoglobin levels. Most notably, unadjusted all-cause mortality escalated steadily from the first to fourth quartiles across all endpoints: in-hospital deaths climbed from 10.5 to 25.7 percent, thirty-day mortality increased from 14.4 to 29.4 percent, ninety-day mortality rose from 18.9 to 38.8 percent, and one-year mortality surged from 25.1 to 47.4 percent.
To evaluate potential nonlinear dependencies between continuous glycemic variability and mortality probability, the researchers performed restricted cubic spline analyses incorporating four knots placed at the fifth, thirty-fifth, sixty-fifth, and ninety-fifth percentiles. The spline models confirmed a statistically significant nonlinear, J-shaped relationship for all four mortality milestones, with likelihood ratio tests yielding p-values below 0.001 for both overall association and nonlinearity. Across each time point, mortality probability demonstrated a modest initial incline at lower variability levels, followed by an abrupt, steep acceleration before eventually plateauing at extreme variability values. By calculating the point along each fitted spline curve that maximized the Youden index, the researchers identified remarkably consistent optimal cut-off values: 0.218 for in-hospital mortality, 0.217 for thirty-day mortality, 0.205 for ninety-day mortality, and 0.210 for 365-day mortality. Averaging these discrete values yielded a unified clinical dichotomization threshold of 0.213, or 21.3 percent, separating patients into high-variability and low-variability cohorts for downstream comparative analyses.
Because patients exhibiting high glycemic variability demonstrated substantial baseline imbalances in age, comorbidities, illness severity, and laboratory parameters, the investigators conducted a rigorous one-to-one propensity score matching analysis to mitigate confounding. The propensity score was constructed using multivariable logistic regression that incorporated all recorded demographic, clinical, vital sign, and laboratory variables, using nearest-neighbor matching without replacement with a caliper width set at 0.15 of the standard deviation of the logit score. While 64.5 percent of evaluated variables exhibited an absolute standardized mean difference exceeding 0.10 before matching, the matched cohort of 1,096 patients—comprising 548 balanced pairs—achieved standardized mean differences below 0.10 across every measured baseline parameter. Despite this rigorous balance in demographics, chronic conditions, and acute physiological severity, patients in the high glycemic variability group continued to exhibit statistically significantly higher mortality rates across every follow-up interval: in-hospital mortality was significantly elevated at p equals 0.001, thirty-day mortality at p equals 0.005, ninety-day mortality at p equals 0.003, and one-year mortality at p equals 0.001.
Multivariable logistic regression models confirmed that elevated glycemic variability maintained an independent, robust association with mortality both before and after propensity matching. In the fully adjusted model applied to the matched cohort, which adjusted for age, sex, comorbidities, laboratory values, and acute illness severity scores, each one percent increase in continuous glycemic variability was associated with an independent increase in mortality risk: the adjusted odds ratio was 1.022 for in-hospital mortality, 1.018 for thirty-day mortality, 1.018 for ninety-day mortality, and 1.016 for one-year mortality. When analyzed as a dichotomous variable based on the 21.3 percent threshold, patients with high variability exhibited an adjusted odds ratio of 1.969 for in-hospital mortality, 1.744 for thirty-day mortality, 1.735 for ninety-day mortality, and 1.815 for one-year mortality. Notably, statistical effect sizes and significance levels remained stable or increased across progressive adjustment models, demonstrating that the adverse impact of glycemic fluctuations operates independently from established baseline risk markers and mean admission glucose concentrations.
The study also assessed whether adding glycemic variability provided incremental predictive power beyond established critical care risk models using receiver operating characteristic curve analyses and DeLong test comparisons. Incorporating glycemic variability into the Oxford Acute Severity of Illness Score significantly enhanced discrimination across all intervals, increasing the in-hospital mortality area under the curve from 0.684 to 0.699 with a p-value of 0.008. Similarly, its addition to the Charlson Comorbidity Index produced significant gains, boosting the in-hospital mortality area under the curve from 0.681 to 0.701 with a p-value of 0.001, with comparable improvements noted at thirty, ninety, and 365 days. In contrast, incorporating glycemic variability into more complex, heavily physiology-based algorithms, such as the Acute Physiology Score III and the Sequential Organ Failure Assessment score, did not yield statistically significant area under the curve increments, though the Sequential Organ Failure Assessment score retained the highest overall baseline predictive accuracy at an area under the curve of 0.782 for in-hospital mortality.
The biological rationale connecting acute glycemic variability to excess mortality in septic trauma involves interconnected pathological cascades central to polytrauma, encompassing systemic inflammation, endothelial barrier breakdown, coagulopathy, and immune suppression. Rapid fluctuations in circulating glucose generate higher levels of reactive oxygen species and cellular oxidative damage than stable hyperglycemia, accelerating lipid peroxidation and destabilizing cell membrane integrity. This pro-oxidant state damages vascular endothelial cells, compromises vascular permeability, and worsens capillary leak syndrome, a central feature of septic shock. Concurrently, acute glycemic swings enhance monocyte-to-endothelial adhesion and induce microvascular vasoconstriction, exacerbating trauma-induced coagulopathy and microvascular thrombosis. In polytrauma patients experiencing concurrent sepsis, these pathological processes form a self-reinforcing vicious cycle where endothelial damage amplifies systemic inflammation, propagating multi-organ failure and compromising long-term physiological resilience.
Despite the statistical rigor of the propensity score matching and multivariable adjustments, the authors acknowledged several inherent study limitations that necessitate cautious interpretation. The retrospective observational design precludes definitive causal claims, as residual or unmeasured confounding factors cannot be completely eliminated. Furthermore, because the dataset was derived from a single academic tertiary medical center in the United States, findings may not fully generalize to healthcare centers with differing demographic compositions or varied trauma management protocols. Additionally, glycemic variability was quantified from intermittent clinical blood glucose measurements whose frequency and timing were determined by clinical discretion rather than rigid research protocols, potentially introducing ascertainment bias. The dataset also lacked detailed records regarding specific nutritional support regimens, detailed insulin titration protocols, and post-discharge rehabilitation care, all of which could influence glycemic patterns and longitudinal survival. Consequently, the authors emphasize that prospective, multi-center clinical trials utilizing standardized glucose monitoring protocols are necessary to determine whether therapeutic interventions actively maintaining glycemic variability below 21.3 percent can improve clinical outcomes.
Subject of Research: Glycemic variability and mortality risk in septic orthopedic trauma patients
Article Title: Glycemic variability improves risk prediction and reveals a mortality threshold in orthopedic trauma patients with sepsis
Article References: Long, Z., Wang, W., Wang, S., Han, T., Lin, F., Li, F., Qin, Y., & Lei, M. (2026). Glycemic variability improves risk prediction and reveals a mortality threshold in orthopedic trauma patients with sepsis. Journal of Orthopaedics and Traumatology, 27(1), Article 52. https://doi.org/10.1186/s10195-026-00940-8
Image Credits: AI Generated
DOI: 10.1186/s10195-026-00940-8
Keywords: glycemic variability, orthopedic trauma, sepsis, critical care, intensive care unit, all-cause mortality, coefficient of variation, restricted cubic spline, propensity score matching, MIMIC-IV database, OASIS score, Charlson Comorbidity Index, endothelial dysfunction, acute kidney injury, dysglycemia, risk stratification


1 hour ago
3




















English (US) ·
French (CA) ·